These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 25368234

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G.
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [Abstract] [Full Text] [Related]

  • 4. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y, Ishikawa E, Asada S, Sugimoto Y.
    Cancer Res; 2005 Jan 15; 65(2):596-604. PubMed ID: 15695404
    [Abstract] [Full Text] [Related]

  • 5. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH, Li G, Yu J, Xu MS, Liu ZX.
    Zhonghua Zhong Liu Za Zhi; 2011 Sep 15; 33(9):654-60. PubMed ID: 22340044
    [Abstract] [Full Text] [Related]

  • 6. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.
    Clin Cancer Res; 2003 Aug 01; 9(8):3052-7. PubMed ID: 12912956
    [Abstract] [Full Text] [Related]

  • 7. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.
    Int J Cancer; 2004 Jan 01; 108(1):146-51. PubMed ID: 14618629
    [Abstract] [Full Text] [Related]

  • 8. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L, Ross DD.
    Oncogene; 2003 Oct 20; 22(47):7340-58. PubMed ID: 14576842
    [Abstract] [Full Text] [Related]

  • 9. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, Stougaard M, Knudsen BR, Moreira J, Hamerlik P, Gajjar M, Smid M, Martens J, Foekens J, Pommier Y, Brünner N, Schrohl AS, Stenvang J.
    BMC Cancer; 2016 Jan 22; 16():34. PubMed ID: 26801902
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE.
    Clin Cancer Res; 2001 Jan 22; 7(1):145-52. PubMed ID: 11205902
    [Abstract] [Full Text] [Related]

  • 15. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.
    Clin Cancer Res; 2002 Jan 22; 8(1):22-8. PubMed ID: 11801536
    [Abstract] [Full Text] [Related]

  • 16. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M.
    Breast Cancer Res Treat; 2013 Jun 22; 139(3):717-30. PubMed ID: 23780685
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y, Lee SH, Sinko PJ.
    Eur J Pharm Sci; 2006 Oct 01; 29(2):102-10. PubMed ID: 16844360
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.
    Arch Otolaryngol Head Neck Surg; 2007 Oct 01; 133(10):1022-7. PubMed ID: 17938326
    [Abstract] [Full Text] [Related]

  • 19. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):594-600. PubMed ID: 16520985
    [Abstract] [Full Text] [Related]

  • 20. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
    Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW.
    Neoplasma; 2005 Nov 01; 52(3):219-24. PubMed ID: 15875083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.